Three-year clinical outcome using the Contura multilumen balloon breast brachytherapy catheter to deliver accelerated partial breast irradiation (APBI): Improving radiation standards for the optimal application of APBI

• Published in: Brachytherapy Vol. 11; no. 4; pp. 316 - 321
• Main Authors: Israel, Philip Z, Robbins, Angela, Shroff, Paulomi, Brown, Sheree, McLaughlin, Mark, Pope, Keith
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2012
• Subjects: Adult; Aged; Balloon brachytherapy; Brachytherapy - instrumentation; Brachytherapy - standards; Breast cancer; Breast Neoplasms - radiotherapy; Catheterization - instrumentation; Catheterization - standards; Contura MLB; Equipment Design; Equipment Failure Analysis; Female; Hematology, Oncology and Palliative Medicine; Humans; Longitudinal Studies; MammoSite; Middle Aged; Partial breast irradiation; Practice Guidelines as Topic; Radiology; Retrospective Studies; Treatment Outcome; United States; United States; MammoSite; Partial breast irradiation; Breast cancer; Contura MLB; Balloon brachytherapy
• ISSN: 1538-4721; 1873-1449
• DOI: 10.1016/j.brachy.2011.07.008

Abstract Purpose We reviewed our institution’s 3-year clinical experience in treating patients with the Contura multilumen balloon (SenoRx, Inc., Aliso Viejo, CA) breast brachytherapy catheter to deliver accelerated partial breast irradiation (APBI). Methods and Materials Forty-six patients treated with breast-conserving therapy received adjuvant radiation using the Contura catheter (34 Gy in 3.4 Gy fractions). Fourteen patients had Stage 0, 24 had Stage I, and 8 had Stage II breast cancer. Median follow-up was 36 months (range, 1–44 months). Results Only one local recurrence developed (2%). The rate of persistent seroma formation at latest reported follow-up was 4.3% (2 patients) and the incidence of any clinically detectable telengiectasias was 2.2%. No major toxicities (0% Grade III) have occurred. The median skin dose (% of the prescribed dose) was 99.7. The median dose to 95% of the planning target volume for evaluation was 98.8%. The percentage of patients with excellent/good cosmetic results at 24 ( n = 23) and 36 ( n = 22) months was 100% and 97%, respectively. Conclusion Adjuvant APBI using the Contura multilumen balloon catheter exhibited similar locoregional control, cosmesis, and toxicities to other forms of APBI with similar lengths of follow-up. In addition, improved radiation standards for the delivery of APBI were demonstrated.